EPRX
Eupraxia Pharmaceuticals Inc.
Biotechnology
Market Cap$250M
5Y Perf.+171.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EPRX vs IRWD
Revenue, margins, valuation, and 5-year total return — side by side.
IRWD
Ironwood Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$680M
5Y Perf.-45.5%
EPRX vs IRWD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EPRX | IRWD |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $250M | $680M |
| Revenue (TTM) | $0.00 | $362M |
| Net Income (TTM) | $-47M | $151M |
| Gross Margin | — | 70.4% |
| Operating Margin | — | 55.3% |
| Forward P/E | — | 3.1x |
| Total Debt | $154K | $598M |
| Cash & Equiv. | $80M | $215M |
EPRX vs IRWD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EPRX
IRWD
| Stock | Apr 24 | May 26 | Return |
|---|---|---|---|
| Eupraxia Pharmaceut… (EPRX) | 100 | 271.9 | +171.9% |
| Ironwood Pharmaceut… (IRWD) | 100 | 54.5 | -45.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EPRX vs IRWD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IRWD leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Eupraxia Pharmaceuticals Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
EPRX
Eupraxia Pharmaceuticals Inc.
The Income Pick
EPRX is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.32
- 153.2% 10Y total return vs IRWD's -59.2%
- Lower volatility, beta 1.32, Low D/E 0.2%, current ratio 15.12x
Best for: income & stability and long-term compounding
IRWD
Ironwood Pharmaceuticals, Inc.
The Growth Play
IRWD carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth -15.7%, EPS growth 400.9%, 3Y rev CAGR -10.3%
- -15.7% revenue growth vs EPRX's -42.8%
- 41.8% margin vs EPRX's 1.7%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IRWD | -15.7% revenue growth vs EPRX's -42.8% |
| Quality / Margins | IRWD | 41.8% margin vs EPRX's 1.7% |
| Stability / Safety | EPRX | Beta 1.32 vs IRWD's 2.50 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IRWD | +426.5% vs EPRX's +97.1% |
| Efficiency (ROA) | IRWD | 38.5% ROA vs EPRX's -70.9%, ROIC 54.0% vs -794.8% |
EPRX vs IRWD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
EPRX vs IRWD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEPRXLAGGINGIRWD
IRWDIronwood Pharmaceutic…
2leads
EPRXEupraxia Pharmaceutic…
3leads
6 Total Categories
CATEGORYLEADERvs IRWDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IRWD1/1
Valuation MetricsMultiples, price ratios, and targets
EPRX1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IRWD4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
EPRX5/6
Risk & VolatilityBeta, volatility, and downside exposure
EPRX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IRWD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IRWD and EPRX operate at a comparable scale, with $362M and $0 in trailing revenue.
| Metric | EPRXEupraxia Pharmace… | IRWDIronwood Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $362M |
| EBITDAEarnings before interest/tax | -$47M | $201M |
| Net IncomeAfter-tax profit | -$47M | $151M |
| Free Cash FlowCash after capex | -$29M | $112M |
| Gross MarginGross profit ÷ Revenue | — | +70.4% |
| Operating MarginEBIT ÷ Revenue | — | +55.3% |
| Net MarginNet income ÷ Revenue | — | +41.8% |
| FCF MarginFCF ÷ Revenue | — | +31.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +158.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -61.9% | +2.0% |
IRWD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
EPRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | EPRXEupraxia Pharmace… | IRWDIronwood Pharmace… |
|---|---|---|
| Market CapShares × price | $250M | $680M |
| Enterprise ValueMkt cap + debt − cash | $170M | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | -7.11x | 27.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 3.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 8.81x |
| Price / SalesMarket cap ÷ Revenue | — | 2.30x |
| Price / BookPrice ÷ Book value/share | 3.72x | — |
| Price / FCFMarket cap ÷ FCF | — | 5.35x |
EPRX leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
IRWD leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), IRWD scores 6/9 vs EPRX's 4/9, reflecting solid financial health.
| Metric | EPRXEupraxia Pharmace… | IRWDIronwood Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | -75.4% | — |
| ROA (TTM)Return on assets | -70.9% | +38.5% |
| ROICReturn on invested capital | -794.8% | +54.0% |
| ROCEReturn on capital employed | -69.7% | +50.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$80M | $382M |
| Cash & Equiv.Liquid assets | $80M | $215M |
| Total DebtShort + long-term debt | $153,953 | $598M |
| Interest CoverageEBIT ÷ Interest expense | — | 8.43x |
IRWD leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
EPRX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in EPRX five years ago would be worth $25,322 today (with dividends reinvested), compared to $3,800 for IRWD. Over the past 12 months, IRWD leads with a +426.5% total return vs EPRX's +97.1%. The 3-year compound annual growth rate (CAGR) favors EPRX at 36.3% vs IRWD's -26.5% — a key indicator of consistent wealth creation.
| Metric | EPRXEupraxia Pharmace… | IRWDIronwood Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -1.3% | -2.3% |
| 1-Year ReturnPast 12 months | +97.1% | +426.5% |
| 3-Year ReturnCumulative with dividends | +153.2% | -60.3% |
| 5-Year ReturnCumulative with dividends | +153.2% | -62.0% |
| 10-Year ReturnCumulative with dividends | +153.2% | -59.2% |
| CAGR (3Y)Annualised 3-year return | +36.3% | -26.5% |
EPRX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
EPRX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EPRX is the less volatile stock with a 1.32 beta — it tends to amplify market swings less than IRWD's 2.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EPRX currently trades 80.2% from its 52-week high vs IRWD's 72.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EPRXEupraxia Pharmace… | IRWDIronwood Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 2.62x |
| 52-Week HighHighest price in past year | $9.32 | $5.78 |
| 52-Week LowLowest price in past year | $3.67 | $0.53 |
| % of 52W HighCurrent price vs 52-week peak | +80.2% | +72.1% |
| RSI (14)Momentum oscillator 0–100 | 54.6 | 68.4 |
| Avg Volume (50D)Average daily shares traded | 198K | 2.5M |
EPRX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates EPRX as "Buy" and IRWD as "Hold". Consensus price targets imply 154.4% upside for EPRX (target: $19) vs 15.1% for IRWD (target: $5).
| Metric | EPRXEupraxia Pharmace… | IRWDIronwood Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $19.00 | $4.80 |
| # AnalystsCovering analysts | 2 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
EPRX leads in 3 of 6 categories (Valuation Metrics, Total Returns). IRWD leads in 2 (Income & Cash Flow, Profitability & Efficiency).
Best OverallEupraxia Pharmaceuticals In… (EPRX)Leads 3 of 6 categories
Loading custom metrics...
EPRX vs IRWD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is EPRX or IRWD a better buy right now?
Ironwood Pharmaceuticals, Inc.
(IRWD) offers the better valuation at 27. 8x trailing P/E (3. 1x forward), making it the more compelling value choice. Analysts rate Eupraxia Pharmaceuticals Inc. (EPRX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — EPRX or IRWD?
Over the past 5 years, Eupraxia Pharmaceuticals Inc.
(EPRX) delivered a total return of +153. 2%, compared to -62. 0% for Ironwood Pharmaceuticals, Inc. (IRWD). Over 10 years, the gap is even starker: EPRX returned +152. 5% versus IRWD's -58. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — EPRX or IRWD?
By beta (market sensitivity over 5 years), Eupraxia Pharmaceuticals Inc.
(EPRX) is the lower-risk stock at 1. 36β versus Ironwood Pharmaceuticals, Inc. 's 2. 62β — meaning IRWD is approximately 93% more volatile than EPRX relative to the S&P 500.
04Which has better profit margins — EPRX or IRWD?
Ironwood Pharmaceuticals, Inc.
(IRWD) is the more profitable company, earning 8. 1% net margin versus 0. 0% for Eupraxia Pharmaceuticals Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRWD leads at 40. 1% versus 0. 0% for EPRX. At the gross margin level — before operating expenses — IRWD leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is EPRX or IRWD more undervalued right now?
Analyst consensus price targets imply the most upside for EPRX: 154.
4% to $19. 00.
06Which pays a better dividend — EPRX or IRWD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is EPRX or IRWD better for a retirement portfolio?
For long-horizon retirement investors, Eupraxia Pharmaceuticals Inc.
(EPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+152. 5% 10Y return). Ironwood Pharmaceuticals, Inc. (IRWD) carries a higher beta of 2. 62 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EPRX: +152. 5%, IRWD: -58. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between EPRX and IRWD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.